Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 4.5 mg subcutaneous once weekly
DULA_SC_4p5MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.43 (-1.88 to -0.87) | 0.62 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.76 (-7.10 to 2.19) | 0.55 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.44 (0.02 to 9.65) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.43 (0.11 to 1.59) | 0.70 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.55 (-10.39 to 3.45) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.64 (0.41 to 0.99) | 0.71 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.80 (0.89 to 3.52) | 0.46 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.43 (2.19 to 5.39) | 0.40 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.46 (2.56 to 7.78) | 0.33 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.28 (1.48 to 3.46) | 0.33 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.55 (1.40 to 4.63) | 0.32 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.80 (0.31 to 10.60) | 0.30 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.75 (0.05 to 11.44) | 0.51 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.57 (0.04 to 9.49) | 0.53 |
Trials
- SURPASS-SWITCHA Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes2022 · 282 randomized · 40 weeks
- AWARD-11A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus2018 · 1,842 randomized · 52 weeks